First Purchase
Note · Biohaven Therapeutics Ltd
Reference: First Purchase
- Original principal
- USD 250,000,000
- Outstanding
- —
- Commitment
- —
- Availability
- —
- Maturity
- —
Verified covenant terms
-
(iv) · Involuntary Disposition
In the event there is any Involuntary Disposition of intangible Collateral, 100% of the aggregate Cash proceeds
Applies to every series under this agreement Exceptions: net of (a) direct, documented out-of-pocket costs incurred in connection therewith that are payable to Third Parties, (b) taxes payable as a result thereof, and (c) the amount necessary to retire any Indebtedness secured by a Permitted Priority Lien on the related property Section 2.2Payments of Repayment Amount, Revenue Payments and Milestone Payments.
Full wording and supporting evidence
Source evidence: (iv)In the event there is any Involuntary Disposition of intangible Collateral, 100% of the aggregate Cash proceeds of such Involuntary Disposition (net of (a) direct, documented out-of-pocket costs incurred in connection therewith that are payable to Third Parties, (b) taxes payable as a result thereof, and (c) the amount necessary to retire any Indebtedness secured by a Permitted Priority Lien on the related property) will be paid promptly (and in any event within 10 Business Days of receipt) to Purchasers and treated as Revenue Payments under this Agreement.
Target identity evidence: This Note Purchase Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is made and dated as of April 28, 2025 (the “Effective Date”) among the Purchasers listed on Schedule 1.1 hereof or otherwise a party hereto from time to time (each a “Purchaser” and collectively, the “Purchasers”), Beetlejuice SA LLC, a Delaware limited liability company, as agent for the Purchasers (in such capacity, “Purchaser Agent”), Biohaven Therapeutics Ltd, a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Issuer”), Biohaven Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Parent”), and the other Obligors from time to time party hereto.
-
(f) · Change of Control
In connection with any Change of Control, the Required Purchasers in their sole discretion may require Issuer to repurchase the Notes
Applies to every series under this agreement Section 2.2Payments of Repayment Amount, Revenue Payments and Milestone Payments.
Full wording and supporting evidence
Source evidence: (f)Change of Control. In the event of any Change of Control, Issuer shall provide at least 10 Business Days’ prior written notice of the anticipated date of such Change of Control to Purchaser Agent and the Purchasers. In connection with any Change of Control, the Required Purchasers in their sole discretion may require Issuer to repurchase the Notes by paying the Repayment Amount, plus all accrued and unpaid Default Interest, all Reimbursable Expenses, and all other outstanding Obligations (other than inchoate indemnity or reimbursement obligations for which no claim has been made) under this Agreement.
Target identity evidence: This Note Purchase Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is made and dated as of April 28, 2025 (the “Effective Date”) among the Purchasers listed on Schedule 1.1 hereof or otherwise a party hereto from time to time (each a “Purchaser” and collectively, the “Purchasers”), Beetlejuice SA LLC, a Delaware limited liability company, as agent for the Purchasers (in such capacity, “Purchaser Agent”), Biohaven Therapeutics Ltd, a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Issuer”), Biohaven Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Parent”), and the other Obligors from time to time party hereto.
-
Section 8.14 · Adverse Regulatory Event; Medicare/Medicaid Reimbursement, Etc.
Section 8.14 Adverse Regulatory Event; Medicare/Medicaid Reimbursement, Etc.. (i) Solely after a Second Purchase Date has occurred, an Adverse Regulatory Event occurs that has had or would be reasonably be expected to result in a Material Adverse Change, or (ii) (A) Parent or any Subsidiary is debarred, excluded, suspended, or otherwise limited from participation in any United States federal health care program or (B) Parent or any Subsidiary is debarred, excluded, suspended for more than 180 days, or…
Applies to every series under this agreement Springing Trigger: Solely after a Second Purchase Date has occurred Exceptions: it being understood and agreed that failure to be included on a formulary shall not constitute an exclusion or limitation from participation for purposes of this Section 8.14 Section 8.14 Adverse Regulatory Event; Medicare/Medicaid Reimbursement, Etc.
Full wording and supporting evidence
Source evidence: Section 8.14 Adverse Regulatory Event; Medicare/Medicaid Reimbursement, Etc.. (i) Solely after a Second Purchase Date has occurred, an Adverse Regulatory Event occurs that has had or would be reasonably be expected to result in a Material Adverse Change, or (ii) (A) Parent or any Subsidiary is debarred, excluded, suspended, or otherwise limited from participation in any United States federal health care program or (B) Parent or any Subsidiary is debarred, excluded, suspended for more than 180 days, or otherwise limited in a manner that has a material and adverse impact on the revenues of Parent and its Subsidiaries, from participation in any United States state health care program (it being understood and agreed that failure to be included on a formulary shall not constitute an exclusion or limitation from participation for purposes of this Section 8.14).
Target identity evidence: This Note Purchase Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is made and dated as of April 28, 2025 (the “Effective Date”) among the Purchasers listed on Schedule 1.1 hereof or otherwise a party hereto from time to time (each a “Purchaser” and collectively, the “Purchasers”), Beetlejuice SA LLC, a Delaware limited liability company, as agent for the Purchasers (in such capacity, “Purchaser Agent”), Biohaven Therapeutics Ltd, a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Issuer”), Biohaven Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Parent”), and the other Obligors from time to time party hereto.
Documents and filing history
- GoverningAgreement · EX-10.1 · 2025-04-28 — EX-10.1
- GoverningAgreement · EX-10.1 · 2025-04-28 — EX-10.1
-
Issuance
· 2025-04-28
Original principal USD 250,000,000 Exact source document
Parent 8-K filing · 2025-04-28
(a)Subject to the terms and conditions of this Agreement (including the conditions precedent set forth in Sections 3.1, 3.2 and 3.5), on the First Purchase Date, the Purchasers agree, severally and not jointly, to purchase Notes from Issuer, and Issuer agrees to issue and sell Notes to each Purchaser, in one purchase according to each Purchaser’s Commitment as set forth on Schedule 1.1 hereto for an aggregate purchase price equal to $250,000,000 (the “First Purchase”).
Issuer evidence: This Note Purchase Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is made and dated as of April 28, 2025 (the “Effective Date”) among the Purchasers listed on Schedule 1.1 hereof or otherwise a party hereto from time to time (each a “Purchaser” and collectively, the “Purchasers”), Beetlejuice SA LLC, a Delaware limited liability company, as agent for the Purchasers (in such capacity, “Purchaser Agent”), Biohaven Therapeutics Ltd, a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Issuer”), Biohaven Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands (“Parent”), and the other Obligors from time to time party hereto. The parties agree as follows:
Supporting evidence: (a)Subject to the terms and conditions of this Agreement (including the conditions precedent set forth in Sections 3.1, 3.2 and 3.5), on the First Purchase Date, the Purchasers agree, severally and not jointly, to purchase Notes from Issuer, and Issuer agrees to issue and sell Notes to each Purchaser, in one purchase according to each Purchaser’s Commitment as set forth on Schedule 1.1 hereto for an aggregate purchase price equal to $250,000,000 (the “First Purchase”).